Sutro Biopharma, Inc. (STRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
STRO POWR Grades
- STRO scores best on the Growth dimension, with a Growth rank ahead of 72.09% of US stocks.
- STRO's strongest trending metric is Quality; it's been moving up over the last 179 days.
- STRO's current lowest rank is in the Stability metric (where it is better than 14.84% of US stocks).
STRO Stock Summary
- With a year-over-year growth in debt of 123.49%, SUTRO BIOPHARMA INC's debt growth rate surpasses 90.17% of about US stocks.
- As for revenue growth, note that STRO's revenue has grown -22.74% over the past 12 months; that beats the revenue growth of merely 7.74% of US companies in our set.
- In terms of volatility of its share price, STRO is more volatile than 90.37% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to SUTRO BIOPHARMA INC are LVTX, MRKR, RARE, EDIT, and FDMT.
- STRO's SEC filings can be seen here. And to visit SUTRO BIOPHARMA INC's official web site, go to www.sutrobio.com.
STRO Valuation Summary
- In comparison to the median Healthcare stock, STRO's EV/EBIT ratio is 120.37% lower, now standing at -2.2.
- STRO's EV/EBIT ratio has moved up 14.9 over the prior 48 months.
Below are key valuation metrics over time for STRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STRO | 2022-09-01 | 5.8 | 1.5 | -2.3 | -2.2 |
| STRO | 2022-08-31 | 5.6 | 1.4 | -2.2 | -2.1 |
| STRO | 2022-08-30 | 5.6 | 1.4 | -2.2 | -2.1 |
| STRO | 2022-08-29 | 5.7 | 1.4 | -2.3 | -2.2 |
| STRO | 2022-08-26 | 5.8 | 1.5 | -2.3 | -2.2 |
| STRO | 2022-08-25 | 6.1 | 1.5 | -2.4 | -2.3 |
STRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STRO has a Quality Grade of D, ranking ahead of 10.85% of graded US stocks.
- STRO's asset turnover comes in at 0.194 -- ranking 205th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows STRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.194 | 1 | -0.301 |
| 2021-03-31 | 0.150 | 1 | -0.169 |
| 2020-12-31 | 0.151 | 1 | -0.155 |
| 2020-09-30 | 0.204 | 1 | 0.118 |
| 2020-06-30 | 0.212 | 1 | -0.081 |
| 2020-03-31 | 0.246 | 1 | -0.444 |
STRO Price Target
For more insight on analysts targets of STRO, see our STRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.38 (Strong Buy) |
STRO Stock Price Chart Interactive Chart >
STRO Price/Volume Stats
| Current price | $5.73 | 52-week high | $23.70 |
| Prev. close | $5.62 | 52-week low | $3.33 |
| Day low | $5.51 | Volume | 56,120 |
| Day high | $5.78 | Avg. volume | 681,984 |
| 50-day MA | $6.01 | Dividend yield | N/A |
| 200-day MA | $8.30 | Market Cap | 298.88M |
Sutro Biopharma, Inc. (STRO) Company Bio
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.
Latest STRO News From Around the Web
Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston. The presentation will be accessible through the News & Events page of the I |
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on August 16, 2022, the Compensation Committee of Sutro’s Board of Directors granted 63,000 Restricted Stock Units of Sutro common stock to three new employees. The grants were made as an inducement material to the employees’ acceptance of employ |
Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a... |
STRO Price Returns
| 1-mo | -13.18% |
| 3-mo | 43.61% |
| 6-mo | -28.02% |
| 1-year | -72.39% |
| 3-year | -39.37% |
| 5-year | N/A |
| YTD | -61.49% |
| 2021 | -31.46% |
| 2020 | 97.36% |
| 2019 | 21.95% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching STRO
Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...